Table 2.

Follow‐up time and characteristics of spironolactone exposure

	Median (interquartile range)
	Overall	Incident users	Prevalent users
Subjects	n = 74 272	n = 52 671	n = 21 601
Total follow‐up time (years)	9.2 (4.2,13.8)	11.3 (7.1,15.3)	3.1 (1.1,7.2)
Exposed follow‐up time (years)	6.9 (2.4,12.2)	9.6 (5.5,13.7)	1.0 (0.2,3.0)
Time after discontinuation (years)	1.3 (0.2,4.2)	1.0 (0.2,3.4)	2.2 (0.3,6.8)
Mean daily dose (mg)	25 (25,50)	25 (25,50)	47 (25,75)
Coverage (%)	98 (79,100)	99 (81,100)	96 (74,100)